News

Altreno is a lotion containing .05% tretinoin, a retinoid that reduces inflammation and lesions associated with acne vulgaris.

A contributing mechanism responsible for the development of idiopathic pulmonary fibrosis has been identified.

The FDA grants an orphan drug designation to a novel gene therapy candidate for the treatment of patients with hereditary angioedema.

The phase 2b dose-ranging trial will involve 216 patients across 12-15 research sites in North America and Europe, beginning in the UK later this month.

The first darunavir-based single tablet regimen for HIV has shown positive results in trials as both a switch therapy and for the rapid initiation of treatment in those who are newly diagnosed.

Ridinilazole caused less microbiota disruption, and investigators believe it may be superior to vancomycin for preventing Clostridium difficile infection recurrence.

The FSA approves lanadelumab (Takhzyro), the first monoclonal antibody approved in the United States to treat patients 12 years and older with types I and II hereditary angioedema.

The Kala Pharmaceuticals therapy INVELTYS becomes the first twice-daily ocular corticosteroid indicated for such treatment.

Howard Levy, MBBCh, PhD, MMM, highlights phase 2/3 trial of MarzAA for the treatment of hemophilia.

Research indicates that rates of Clostridium difficile infection among those typically not considered at high risk of infection are increasing, and these infections are becoming more frequent, severe, and difficult to treat.

The FDA has granted a rare pediatric disease designation to Krystal Biotech’s KB105 for the treatment of patients with TGM-1-deficient autosomal recessive congenital ichthyosis.

Use of this new approach suggests that HCV infection burden in New York City has been underestimated in populations considered high-risk for HCV, and that HCV transmission has increased among young adults in the city.

Phase 3 data for ibalizumab showed that nearly half of patients had a reduction in viral load of more than 80% after 25 weeks of therapy.

In a clinical trial, the expedited Transcranial Magnetic Stimulation device produced a patient response/remission rates of 32% depressive symptom improvement rates of 49%.

Oxervate eye drops, which contain cenegermin, are the first approved treatment for a rare condition that affects fewer than 5 in 10,000 individuals.

The FDA approves the first drug, cenegermin, for the treatment of neurotrophic keratitis, a rare disease affecting the cornea.

Investigators have discovered a mechanism that could reduce the toxic aggregation of huntingtin protein, which is responsible for neurodegeneration in patients with Huntington’s disease.

A potential first-in-class, oral medication to treat uterine fibroids has been accepted by the FDA.

The new test should replace the water deprivation test as the new standard of care, investigators say.

In an analysis of 118 clinical trials since 2001, investigators found females and minorities comprised just 27% and 22% of the total patient population, respectively.

Results from a 12-month extension study show that elagolix taken with hormone therapy reduced menstrual blood loss in 87.9% of women with uterine fibroids.

The study authors state these data can be used to develop a tailored approach to the elimination of hepatitis C virus infection, worldwide.

The results of a new meta-analysis revealed metronidazole was among the worst choices for treating the infection.

A team of investigators at Cleveland Clinic discover a novel subtype of multiple sclerosis which features neuronal loss but no demyelination of the brain’s white matter.

Cleveland Clinic investigators have discovered a novel form of the neurological condition which does not demyelinate the brain's white matter.

The FDA grants RMAT designation to AT132 for the treatment of patients with X-linked Myotubular Myopathy.

Stiripentol (Diacomit) has been approved for treatment in patients 2 years of age and older with Dravet syndrome, a rare form of epilepsy.

A rapid genetic diagnostic tool coupled with a sustained release therapeutic is being developed for lower-grade gliomas by a team of investigators.